Vol.

No.

September 29, 2023Sep 29, 2023

DOWNLOAD THE PDF

ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution”

Cover Story

Clinical

ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution”

If you’ve been following the saga of drug shortages in this publication, you know how America’s cancer institutions are scrambling to obtain platinum-based drugs for their patients.

Capitol Hill

Most NIH activities will cease immediately if government shuts down

By Matthew Bin Han Ong

Film & TV Free

Women physicians are underrepresented in film, a study led by oncologists finds

By Alexandria Carolan

Guest Editorial

“Oppenheimer” is a reminder to physicians, scientists to act to prevent nuclear war

By Robert Peter Gale and Andreas Hochhaus

Free

NCI’s SEER marks 50 years of cancer surveillance

In Brief

ARPA-H establishes health innovation network

Cancer Research UK, France’s Institut National du Cancer enter €10M partnership to advance cancer research

WashU and Siteman receive $11.6M SPORE grant for endometrial cancer research

The New Mexico Cancer Care Alliance rebrands as the New Mexico Cancer Research Alliance

Lekhaj Daggubati named director of surgical neuro-oncology at GW Cancer Center

$3.7M grant to fund tobacco research center at UC Davis Comprehensive Cancer Center

UCLA’s Mina Sedrak receives $3.4M from NIH to study accelerated aging in breast cancer survivors

Community Foundation of Broward assists research efforts at Memorial Cancer Institute

Kaitlyn O’Keefe joins Oncology Specialists of Charlotte

Clinical Roundup

Phase III Mariposa study evaluating Rybrevant + lazertinib meets primary endpoint in PFS in NSCLC

Elahere demonstrates OS, PFS benefit regardless of prior PARPi exposure or prior lines of therapy in ovarian cancer

Sylvester study: New protocols enable many patients to safely return home one day after lung cancer surgery

Salk researchers find that stress hormones exhaust immune cells in humans and mice, beta-blockers can help

Drugs & Targets

FDA approves Bosulif for pediatric patients with CML

FDA clears automated assay to assess tumor progression in neuroendocrine cancer

Mythic Therapeutics receives FDA Fast Track designation for MYTX-011 in NSCLC with cMET overexpression

Pierre Fabre Laboratories, Vernalis partner to advance cancer research

Mission Bio develops single-cell MRD assay

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 06 - February 13, 2026